JP2022520859A5 - - Google Patents

Info

Publication number
JP2022520859A5
JP2022520859A5 JP2021548200A JP2021548200A JP2022520859A5 JP 2022520859 A5 JP2022520859 A5 JP 2022520859A5 JP 2021548200 A JP2021548200 A JP 2021548200A JP 2021548200 A JP2021548200 A JP 2021548200A JP 2022520859 A5 JP2022520859 A5 JP 2022520859A5
Authority
JP
Japan
Prior art keywords
cancer
rorγ
composition according
pharmaceutical composition
jte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019118 external-priority patent/WO2020172467A1/en
Publication of JP2022520859A publication Critical patent/JP2022520859A/ja
Publication of JP2022520859A5 publication Critical patent/JP2022520859A5/ja
Pending legal-status Critical Current

Links

JP2021548200A 2019-02-20 2020-02-20 レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療 Pending JP2022520859A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962808231P 2019-02-20 2019-02-20
US62/808,231 2019-02-20
US201962881890P 2019-08-01 2019-08-01
US62/881,890 2019-08-01
US201962897202P 2019-09-06 2019-09-06
US62/897,202 2019-09-06
US201962903595P 2019-09-20 2019-09-20
US62/903,595 2019-09-20
US202062959607P 2020-01-10 2020-01-10
US62/959,607 2020-01-10
PCT/US2020/019118 WO2020172467A1 (en) 2019-02-20 2020-02-20 Treatment for retinoic acid receptor-related orphan receptor ɣ (rorɣ)-dependent cancers

Publications (2)

Publication Number Publication Date
JP2022520859A JP2022520859A (ja) 2022-04-01
JP2022520859A5 true JP2022520859A5 (https=) 2023-02-28

Family

ID=72144161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548200A Pending JP2022520859A (ja) 2019-02-20 2020-02-20 レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療

Country Status (5)

Country Link
US (1) US20220202811A1 (https=)
EP (1) EP3927329A4 (https=)
JP (1) JP2022520859A (https=)
CN (1) CN113710239A (https=)
WO (1) WO2020172467A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149786A1 (en) * 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2024229569A1 (en) * 2023-05-09 2024-11-14 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629910B2 (en) * 2011-03-22 2017-04-25 The Brigham And Women's Hospital, Inc. Use of Th9 cells and IL-9 for the treatment of melanoma
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
US9359315B2 (en) * 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
JP6564029B2 (ja) * 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
CN107614062A (zh) * 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
SI3294713T1 (sl) * 2015-05-15 2021-08-31 Aurigene Discovery Technologies Limited, Nadomeščene spojine tetrahidrokinolinona kot ROR gama modulatorji
WO2017079120A1 (en) * 2015-11-04 2017-05-11 The Scripps Research Institute Ror gamma agonists as enhancers of protective immunity
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors

Similar Documents

Publication Publication Date Title
JP7492002B2 (ja) Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法
JP2024015120A5 (https=)
RU2012147739A (ru) Пероральные составы, содержащие аналоги цитидина, и способы их использования
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
JP2024527109A5 (https=)
Tewes et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study
JP2022504468A5 (https=)
JP2022520859A5 (https=)
NO331486B1 (no) Anvendelse av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin ogsa kjent som ZD6474, eller et farmasoytisk akseptabelt salt derav og ±n av: a) 5-FU; b)CPT-11; og c)5-FU og CPT-11, ved fremstilling av et medikament for anvendelse ved behandling av kreft hos et varmblodig dyr sa som et menneske, samt farmasoytisk preparat og sett inneholdende samme
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
Engelsman et al. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study.
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
CN112741833A (zh) 西达本胺及其衍生物的用途
TWI813331B (zh) β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途
CA3135916C (en) COMBINED USE OF THE COMPOUND MEDICINE A-NOR-5A ANDROSTANE AND AN ANTI-CANCER MEDICINE
US8663711B2 (en) Use of armillaridin for treating cancer
RU2010139840A (ru) Комбинация противораковых агентов
JP2022504760A5 (https=)
CN113082037B (zh) 小分子组合物在制备治疗肝内胆管细胞癌药物中的应用
CN111728960B (zh) 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用
US20040266704A1 (en) Method comprising irinotecan for treatment of breast cancer
SU731967A1 (ru) Способ лечени воспалительных заболеваний легких
Choy et al. Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer
Hofheinz et al. Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
EP4288050A1 (en) Combination therapy for cancer treatment